Stocks Health care ANTX
NASDAQ · Health careAN2 Therapeutics, Inc. (ANTX)
It posted a net loss of $34.9M. At September 30, 2026 it held $20.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about AN2 Therapeutics, Inc.
- Net worth
- AN2 Therapeutics, Inc. has a market value (market cap) of $163.4M at the latest share price, and shareholders' equity of $75.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $29.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- AN2 Therapeutics, Inc.'s next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What AN2 Therapeutics, Inc. does
AN2 Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$35.2M | -$1.16 | n/a |
| 2024 | n/a | -$51.3M | -$1.72 | n/a |
| 2023 | n/a | -$64.7M | -$2.74 | n/a |
| 2022 | n/a | -$41M | -$2.79 | n/a |
| 2022 | n/a | -$21.5M | -$10.64 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What AN2 Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- September 14, 2026
- August 11, 2026
- August 11, 2026
- June 9, 2026
- June 4, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 11, 2026
- May 11, 2026
Insider trades
What the people running AN2 Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $11.6K and sold $330.1K worth of shares in the last 90 days. Most of the selling (96%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Eizen Joshua MSee Remarks | Sold | 2,826 | $11.9K |
| October 12, 2026 | Aziz KabeerDirector | Received as pay | 2,465 | - |
| October 12, 2026 | Martin Patricia A.Director | Received as pay | 389 | - |
| October 12, 2026 | Marks Gilbert LynnDirector | Received as pay | 2,283 | - |
| September 15, 2026 | Trenor Cameron C. IIIChief Medical Officer | Received as pay | 116,667 | - |
| September 9, 2026 | Readnour Robin ShaneDirector | Soldpre-planned (10b5-1), indirect | 523 | $3.2K |
| September 9, 2026 | Readnour Robin ShaneDirector | Soldpre-planned (10b5-1), indirect | 585 | $3.5K |
| September 8, 2026 | Readnour Robin ShaneDirector | Soldpre-planned (10b5-1), indirect | 4,725 | $28.4K |
Who owns ANTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Commodore Capital LP13G, passive with 3 related filers | 9.9% | March 16, 2026 |
| Coastlands Capital LP13G, passive with 4 related filers | 9.3% | June 4, 2025 |
| Vivo Opportunity Fund Holdings, L.P.13G, passive with 3 related filers | 8% | March 13, 2026 |
| Adjuvant Capital GP, L.P.13G, passive with 3 related filers | 7.9% | February 28, 2025 |
| Eric Easom13G, passive | 7.9% | February 13, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 6.3% | March 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 66 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Vivo Capital, LLC | 3,153,640 | 0 |
| Commodore Capital LP | 2,933,680 | +599,967 |
| Millennium Management LLC | 2,318,692 | +96,190 |
| BlackRock, Inc. | 1,665,494 | +1,346,726 |
| Spruce Street Capital LP | 1,661,073 | 0 |
| Almitas Capital LLC | 1,469,129 | -10,000 |
| Vanguard Capital Management LLC | 1,238,705 | +227,627 |
| Adage Capital Partners GP, L.L.C. | 1,000,000 | 0 |
| Citadel Advisors LLC | 951,997 | +796,758 |
| Boxer Capital Management, LLC | 749,035 | 0 |
| Geode Capital Management, LLC | 697,806 | +411,259 |
| SummitTX Capital, L.P. | 597,453 | new |
| Balyasny Asset Management L.P. | 556,027 | new |
| Stonepine Capital Management, LLC | 551,692 | -162,153 |
| Ameriprise Financial Inc | 537,064 | -159,117 |
| Sio Capital Management, LLC | 529,933 | -127,267 |
| Ally Bridge Group (NY) LLC | 526,315 | 0 |
| Prosight Management, LP | 474,638 | -41,116 |
| Woodline Partners LP | 459,805 | -533,866 |
| State Street Corp | 311,602 | +196,400 |
Insiders
12 insiders reported holding 1,855,878 shares in total, about $8M at the last price.
| Holder | Shares |
|---|---|
| Readnour Robin ShaneDirector | 624,765624,765 held indirectly |
| Easom EricChief Executive Officer, Director | 368,630 |
| Eizen Joshua MSee Remarks | 207,546 |
| Chanda SanjayChief Development Officer | 118,823 |
| Day LucyChief Financial Officer | 118,363 |
| Trenor Cameron C. IIIChief Medical Officer | 116,667 |
| Marks Gilbert LynnDirector | 84,156 |
| Williams Sarah JoannePrincipal Accounting Officer | 66,311 |
| Aziz KabeerDirector | 61,571 |
| Prior Stephen DavidChief Strategy Officer | 59,086 |
Questions about ANTX
What does AN2 Therapeutics, Inc. do?
AN2 Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ANTX. Its shares trade on NASDAQ under the ticker ANTX.
What is AN2 Therapeutics, Inc.'s net worth?
AN2 Therapeutics, Inc. has a market value (market cap) of $163.4M at the latest share price, and shareholders' equity of $75.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is AN2 Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $34.9M.
When did AN2 Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is AN2 Therapeutics, Inc.'s next earnings report?
AN2 Therapeutics, Inc.'s next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ANTX with
Follow ANTX
Get an email when AN2 Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values AN2 Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.